65,437 trials
Open-Angle Glaucoma · Ocular Hypertension
Primary: Mean Intraocular Pressure (IOP) at Each Assessment Timepoint (8 AM, +2 h, +7 h, and +9 h) at Month 3 — 21.1; 22.0; 23.2; 18.0 millimeters mercury (mm HG)
End Stage Renal Disease
Primary: Percent of Subjects That Achieved Controlled Serum Phosphorous Levels on Calcium-based Phosphate Binder Therapy — 14.9 percentage of subjects
Atopic Dermatitis · Secondary Infection
Primary: Bacteriological Culture — 13; 3; 16; 5 participants
Peripheral Neuropathy
Primary: Nerve Conduction Velocity (Meters Per Second) — 0.000; -0.358; 0.447; 0.147 m/s
Dehydration
Primary: Maximum IVC Diameter — 38; 64 mm
Herpes Zoster · Shingles
Primary: Geometric Mean Titer (GMT) of Varicella-Zoster Virus (VZV) Antibody — 235.7; 208.2; 532.6; 457.1 Units/mL — p=<0.001
Hypercholesterolemia
Primary: LDL Cholesterol — -44.7; -27.1 % change in LDL cholesterol
Squamous Cell Carcinoma of Head and Neck
Primary: Partial Response Rate in Both Groups of Patients. — 7; 13 percentage of participants
Osteoarthritis, Knee
Primary: Change From Baseline in Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) Score at Day 30 — -22.2; -21.5; -29.5; -73.2 Millimeter (mm)
Heart Failure
Primary: Exercise Capacity, as Determined by Peak Oxygen Uptake — -0.07; -0.12 ml/min/kg
Pain · Fibromyalgia
Primary: Pain Visual Analog Scale Score at Day 14 — 53.0 Millimeter (mm)
Hematologic Neoplasms · Neutropenia · Fever
Primary: Percentage of Participants Achieving Plasma Level of Itraconazole at 1000 Nanogram Per Milliliter (ng/mL) or Higher After Administration of Study Treatment — 68.0…
Varicella
Primary: Percentage of Participants With One or More Adverse Events (AEs) — 37.69 Percentage of Participants
Chronic Migraine
Primary: Percent Change of Migraine Headache Days Compared to Baseline — -8.06; -56.37 percent migraine headache days per month
Corneal Neovascularization
Primary: Adverse Events (Ocular and Systemic) — 0 participants